Core Viewpoint - Sanofi Biologics (300298.SZ) currently does not have a dedicated testing product for detecting Chikungunya virus disease [1] Group 1: Company Overview - The company utilizes biosensor technology to develop, produce, and sell a series of rapid diagnostic products for chronic disease patients and healthcare professionals [1] - It also provides related professional services and digital health management for diabetes [1]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-068 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第三期员工持股计划第二次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 二、会议审议情况 三、备查文件 1、三诺生物传感股份有限公司第三期员工持股计划第二次持有人会议决议。 特此公告。 本次会议采用现场表决方式进行表决，经与会持有人认真审议，本次会议形 成以下决议： （一）审议并通过《关于变更第三期员工持股计划管理委员会委员的议案》 鉴于第三期员工持股计划管理委员会委员于媛媛因个人原因无法继续履职， 根据《第三期员工持股计划（草案修订稿）》《第三期员工持股计划管理办法》相 关规定，为保证公司第三期员工持股计划管理委员会的正常运作，有效保障全体 持有人的合法权益，选举闵晓芳为公司第三期员工持股计划管理委员会委员，与 原委员高飞、高奥共同组成公司第三期员工持股计划管理委员会，任期与公司第 三期员工持股计划的存续期一致 ...

Group 1 - The company announced a share buyback program, having repurchased a total of 3,868,600 shares as of July 31, 2025 [2] - The repurchased shares represent 0.69% of the company's total share capital, which is 560,266,088 shares [2]

格隆汇8月1日丨三诺生物(300298.SZ)公布，截至2025年7月31日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购公司股份3,868,600股，占公司当前总股本560,266,088股的比例为0.69%，本次 回购股份的最高成交价为21.39元/股，最低成交价为19.41元/股，成交总金额为79,920,950.54元（不含交 易费用）。本次回购符合公司既定的回购方案及相关法律法规的要求。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-067 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 一、回购股份的进展情况 截至 2025 年 7 月 31 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 3,868,600 股，占公司当前总股本 560,266,088 股的比例为 0.69%，本次回购股份的最高成交价为 21.39 元/股，最低成交价为 19.41 元/股， 成交总金额为 79,920,950.54 元（不含交易费用）。本次回购符合公司既定的回购 方案及相关法律法规的要求。 二、其他说明 （一）公司回购股份的时间、回购股份的数量、回购股份价格及集中竞价交 易的委托时段均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等法律法规的相关规定。 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成 ...

Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Viewpoint - Sanofi Biologics has voluntarily withdrawn its first-generation Continuous Glucose Monitoring (CGM) product's FDA registration application to expedite the entry of the next-generation solution into the U.S. market [1][2] Group 1: FDA Registration Withdrawal - The company received confirmation from the FDA regarding the withdrawal of its first-generation CGM product's registration application [1] - The first-generation CGM product, iCani3, had met the FDA's iCGM performance standards, but the clinical data was insufficient to demonstrate substantial equivalence to recently approved iCGM products [1] Group 2: Focus on Next-Generation Products - The company has completed the development of its second-generation CGM product, which has been launched domestically and offers improved user convenience and comfort [2] - The second-generation CGM product has also received CE-MDR certification in Europe, allowing it to be sold in countries that recognize the EU MDR qualifications [2] Group 3: Global Expansion Strategy - Globalization is a key task for the company by 2025, with CGM products already launched in over 60 countries and regions as of April [2] - The company is advancing local sales in regions such as the Middle East, Southeast Asia, and Eastern Europe through diverse business models, including distributors and localized operations [2]

Core Points - The closing price of Sanofi Biologicals on July 30 was 21.22 yuan, down 1.03%, with a rolling PE ratio of 37.45 times and a total market value of 11.889 billion yuan [1] - The average PE ratio in the medical device industry is 55.15 times, with a median of 37.48 times, placing Sanofi Biologicals at the 75th position in the industry ranking [1] - On July 30, the net outflow of main funds for Sanofi Biologicals was 5.5516 million yuan, but over the past five days, there was a total inflow of 61.8244 million yuan [1] - Sanofi Biologicals specializes in the production and sales of blood glucose monitoring systems and has received multiple national recognitions for its technological advancements and innovation [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while net profit was 72.1151 million yuan, a year-on-year decrease of 10.90%, with a gross profit margin of 48.69% [1] Industry Summary - The average PE ratio for the medical device industry is 55.15 times, while the median is 37.48 times [2] - The PE ratio for Sanofi Biologicals is 37.45 times, which is below the industry average but aligns with the median [2] - Other companies in the industry have varying PE ratios, with the highest being 20.21 times for Antu Biology and the lowest at 11.07 times for Jiuan Medical [2]

Core Viewpoint - Sanofi Biologics has voluntarily withdrawn its 510(K) application for the first-generation continuous glucose monitoring system iCan i3 to expedite the entry of the next-generation solution into the U.S. market [1] Group 1: Product Development - The first-generation continuous glucose monitoring system iCan i3 has met the performance standards required by the FDA for iCGM, but the clinical data completed is statistically insufficient to demonstrate substantial equivalence to recently approved iCGM products [1] - The company has decided to focus resources on advancing the next-generation product due to the potential need for additional clinical research [1] Group 2: Regulatory Achievements - The latest generation continuous glucose monitoring system iCan i6 has obtained CE-MDR certification in the European Union [1] - The company aims to combine the high accuracy and reliability of the i3 system with greater usability and affordability to continue supporting global continuous glucose monitoring system users [1]